On 12 Nov 2026 McKesson closed at $1,077.05, +31.7% this year; market cap $125.69bn, P/E 26.7.
Health Care · Health Care Distributors · NYSE · United States
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, hospital reference labs, nursing homes, hospice and home health care agencies, government facilities, and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
| Market cap | $125.69bn |
| P/E (trailing) | 26.7 |
| EPS (TTM) | $40.27 |
| Beta | 0.28 |
| Dividend | $3.76 |
| Dividend yield | 0.35% |
| Ex-dividend date | 1 Dec 2026 |
| Latest report | 4 Nov 2026 |
| Next earnings | 3 Feb 2027 |
| YTD | +31.7% |
| 1Y | +28.6% |
| 3Y | +32.4% |
| 5Y | +37.5% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2026 | $403.43bn | $4.76bn | $5.41bn |
| 2025 | $359.05bn | $3.29bn | $5.23bn |
| 2024 | $308.95bn | $3.00bn | $3.63bn |
| 2023 | $276.71bn | $3.56bn | $4.60bn |
| 2022 | $263.97bn | $1.11bn | $3.90bn |
Base value $778.87 (-27.7% vs price); 0 of 1 methods above the price. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.